Evaluate Safety, Efficacy and Pharmacokinetics

A Double-Blind, Randomized, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics, and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer

The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

Patients will receive CT-P6 or Herceptin.

Inclusion Criteria:

• Are females
• Have a Her 2 over-expression
• Have Eastern Cooperative Oncology Group (ECOG) 0 or 1

Exclusion Criteria:

• Current clinical or radiographic evidence central nervous system (CNS) metastases
• Current Known infection
• Pregnant or nursing mother